Breakthrough High-Throughput Platform Yields Fast-Acting Covalent Protein Drugs

Revolutionary High-Throughput Platform for Covalent Protein Drugs

Westlake University has taken a monumental step in drug development with the unveiling of a high-throughput platform designed to create fast-acting covalent protein therapeutics. Spearheaded by key researchers Bobo Dang and Ting Zhou, this innovative platform was thoroughly detailed in a recent publication in Science.

Covalent small-molecule drugs have gained ground in cancer therapies due to their ability to form irreversible bonds with target proteins. Driven by the success of these drugs, researchers have sought to adapt similar covalent strategies for protein therapeutics, particularly engineered miniproteins. However, the rapid clearance of miniproteins from the body presents a challenge, as their covalent bond formation typically occurs at a slower pace. Hence, there has been a notable gap in high-throughput platforms capable of optimizing covalent protein reactivity efficiently.

To tackle this problem, Dang and Zhou proposed an ingenious solution: precisely positioning chemical warheads within protein structures to facilitate molecular preorganization. This spatial arrangement allows for accelerated covalent bond formation without necessitating higher intrinsic reactivity.

The newly developed platform utilizes yeast surface display along with chemoselective protein modifications to sift through a diverse range of crosslinkers and millions of protein variants. By optimizing the placement of warheads and their surrounding chemical environments, the platform enables swift and irreversible engagement with target proteins.

One significant outcome of this research is the development of a covalent antagonist for PD-L1, known as IB101. Structural analyses corroborate that IB101 forms a well-defined pocket ensuring the warhead is positioned optimally, significantly hastening the formation of covalent bonds. Functionally, IB101 effectively inhibits the PD-1/PD-L1 immune checkpoint pathway and demonstrates substantial antitumor activity in mouse models. Remarkably, although IB101 has a short half-life in the body, it achieves sustained target engagement and tumor suppression, performing better than traditional antibody therapies under similar conditions.

The platform's versatility extends beyond immunotherapy. It has been adapted for cytokine engineering, resulting in the creation of a covalent variant of IL-18, termed IB201. This variant adeptly forms covalent interactions with its receptor, strengthening and prolonging its signaling. In vivo investigations indicated that IB201 spurs potent antitumor immune responses without causing systemic toxicity, emphasizing the potential of covalent engineering in enhancing cytokine-based therapies.

Additionally, the platform was employed to devise a covalent inhibitor aimed at the receptor-binding domain of SARS-CoV-2. This breakthrough demonstrates sustained viral neutralization, underscoring the method's adaptability across diverse therapeutic areas.

Through this groundbreaking study, a new foundation for crafting fast-acting covalent protein therapeutics has been established. By enabling covalent bond formation to occur in parallel with rapid clearance from the body, the platform effectively addresses a crucial limitation in this research area. These findings have wide-ranging implications, potentially revolutionizing approaches to cancer immunotherapy, antiviral strategies, and beyond.

In conclusion, the work put forth by the team at Westlake University is poised to reshape the landscape of protein therapeutics, providing a novel framework for designing biologics that deliver both rapid action and sustained pharmacological effects.